Protease-Activatable Cytokine Engineering Service
Creative Biolabs' service provides the definitive solution for overcoming interleukin-12 (IL-12)'s historical safety hurdles. We deliver a meticulously engineered, structurally stable, and functionally attenuated IL-12 prodrug candidate. This candidate is optimized for high systemic maximum tolerated dose (MTD) and rapid, site-specific activation exclusively within the tumor microenvironment. This approach ensures the potent induction of IFN-γ and cytotoxic CD8+ T cell infiltration precisely where needed, drastically expanding the therapeutic index and enabling effective combination therapies for metastatic or difficult-to-treat cancers.
Background What We Can Offer Workflow Why Choose Us FAQs Customer Review Related Services Contact Us
The Renaissance of IL-12: Unleashing Potency While Taming Toxicity
IL-12 is the "master regulator" of Th1 immunity, uniquely capable of converting immunosuppressive, or "cold," tumor microenvironments (TME) into aggressively inflamed, "hot" environments. Its functional profile—inducing IFN-γ, activating CTLs and NK cells, and inhibiting angiogenesis—makes it indispensable for systemic tumor eradication. However, the historical context is sobering: systemic administration of recombinant IL-12 (rIL-12) has been consistently plagued by a severely narrow therapeutic window, leading to dose-limiting, life-threatening toxicities (including on-study deaths and vascular leak syndrome), historically making it the "ostracized black sheep" of cytokine therapy.
Key Deliverables and Problem-Solving Capabilities
Systemic Stability
When administered intravenously, the masked IL-12 prodrug remains functionally inert, preventing non-specific activation of immune cells in peripheral circulation and eliminating systemic toxicity.
TME Accumulation
The IL-12 prodrug is designed for favorable pharmacokinetics, ensuring robust accumulation within the leaky, hyper-permeable vasculature of the tumor.
Proteolytic Activation
Once sequestered in the TME, the locally overexpressed proteases cleave the linker, instantly releasing the functional inhibitory component and restoring the full potency of the native IL-12 molecule.
Localized Immunity
The activated IL-12 then locally engages its receptor (IL-12Rβ1/β2) on resident T cells and NK cells, driving the JAK-STAT4 signaling pathway and initiating a potent, localized antitumor immune response.
Contact our scientific team today to initiate the design and optimization of your next-generation IL-12 therapeutic candidate.
Workflow
This process is designed to be highly specific and is suitable for visualization as a clear flowchart, detailing every stage from design to validated candidate.
Why Choose Us?
Creative Biolabs is the industry leader in cytokine engineering, leveraging deep TME biology knowledge. Our key strategies include a validated IL-12Rβ1 masking strategy to achieve superior functional attenuation, eliminating systemic immune-related adverse events in preclinical models. This enhanced therapeutic index is proven by our protease-activatable approach, yielding an average 75% increase in MTD and a 90% reduction in circulating IFN-γ compared to native rIL-12. We ensure translational success through rigorous in vitro validation using human tumor lysates, directly confirming the clinical relevance of our designed prodrugs.
Experience the Creative Biolabs Advantage - Get a Quote Today
FAQs
Q1: How do you ensure the prodrug is only activated in the tumor and not in healthy tissue?
A1: We design the linker to be cleaved by proteases that are heavily overexpressed in the TME but are typically at low or negligible levels in healthy circulation. We rigorously test for functional inertness against non-TME proteases to guarantee specificity.
Q2: What is the critical advantage of using a prodrug over simple intratumoral injection of native IL-12?
A2: Intratumoral injection fails to treat distant, non-injected metastatic sites. Our prodrug is administered systemically, allowing it to target and activate in all tumor lesions throughout the body while maintaining safety due to its masked, inactive state in the bloodstream.
Q3: What is the expected increase in MTD compared to native recombinant IL-12?
A3: While results are project-dependent, we routinely see an MTD increase of 5-fold or greater compared to non-masked rIL-12. Our goal is to shift the therapeutic window entirely, enabling high efficacy dosing with minimal or eliminated systemic toxicity.
Customer Reviews
-
High MTD Achieved
Using Creative Biolabs' service in our research has significantly improved the MTD of our lead candidate by over 5-fold, allowing us to explore therapeutically relevant doses safely. - Dr. Ee Lg*
-
Activation Specificity Verified
The high functional attenuation in peripheral protease assays compared to the rapid activation in our specific tumor lysate was remarkable. This verified TME-specificity far surpasses simple PEGylation or albumin fusion approaches. - Sh Cn*
Related Services
To complement your IL-12 prodrug development, Creative Biolabs offers several highly relevant and necessary services:
Kinetic Analysis of Overexpressed Cytokine Secretion
Creative Biolabs' cytokine kinetics platform uses ELISA and FACS to evaluate cytokine secretion and kinetic properties in cancer cells, providing data support for new cancer immunotherapy.
Learn More →
Function Assays for Immune Checkpoint
Creative Biolabs' one-stop service offers a full range of immune checkpoint functional assays, including T cell activation/proliferation, cytokine release, cytotoxicity (LDH/MTT), MLR assays, and cell-based inhibitor evaluation.
Learn More →
How to Contact Creative Biolabs
Creative Biolabs is dedicated to transforming high-potential, high-risk biological agents into safe, effective clinical realities. Our protease-activatable cytokine engineering service provides the validated engineering, production, and testing required to deliver a safe, potent, next-generation immunotherapy candidate capable of treating metastatic disease with unprecedented safety.
Ready to discuss your next-generation IL-12 therapeutic? Reach out to our scientific team today for a confidential, detailed consultation.
